

Filed: May 25, 2016

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TEVA PHARMACEUTICALS USA, INC.,
Petitioner,

v.

INDIVIOR UK LIMITED,
Patent Owner.

Case IPR2016-00280
Patent 8,475,832

PETITIONER'S UPDATED EXHIBIT LIST

Pursuant to 37 C.F.R. § 42.63(e), Petitioner submits the following current exhibit list:

Exhibit No.	Reference
1001	U.S. Patent No. 8,475,832 (filed August 7, 2009)
1002	File History, U.S. Patent No. 8,475,832
1003	Expert Declaration of Nandita Das, Ph.D., Relating to U.S. Patent No. 8,475,832
1004	U.S. Patent Application Publication 2005/0085440 (published April 21, 2005) (“Birch”)
1005	WO 2008/025791 (published March 6, 2008) (“Oksche”)
1006	U.S. Patent No. 7,357,891 (published December 23, 2004) (issued April 15, 2008) (“Yang”)
1007	WO 2008/040534 (published April 10, 2008) (“LabTec”)
1008	Suboxone® Label
1009	Suboxone® Tablet Summary Basis of Approval (“SBOA”)
1010	U.S. Patent Application Publication No. 2005/0037055 (“the ’055 publication”)
1011	European Medicines Agency Initial Marketing-Authorisation Document, Scientific Discussion, Oct. 19, 2006 for Suboxone sublingual tablets (“EMEA”)
1012	J.P. Cassidy et al., <i>Controlled Buccal Delivery of Buprenorphine</i> , 25 J. Controlled Release 21 (1993)
1013	Rex M. C. Dawson et al., <i>Data for Biochemical Research</i> (3d ed. 1986)

1014	Domenic A. Ciraulo et al., <i>Pharmacokinetics and Pharmacodynamics of Multiple Sublingual Buprenorphine Tablets in Dose-Escalation Trials</i> , 46 J. Clinical Pharmacology 179 (2006)
1015	C. Nora Chiang & Richard L. Hawks, <i>Pharmacokinetics of the Combination Tablet of Buprenorphine and Naloxone</i> , 70 Drug & Alcohol Dependence S39 (2003)
1016	Campbell et al., <i>The History of the Development of Buprenorphine as an Addiction Therapeutic</i> , 1248 Ann. N.Y. Acad. Sc. (Issue: <i>Addiction Reviews</i>), 124 (2012) (“Campbell”)
1017	Bullingham et al., <i>Sublingual Buprenorphine Used Postoperatively: Clinical Observations and Preliminary Pharmacokinetic Analysis</i> , 12 Br. J. Clinical Pharmacology 117 (1981)
1018	U.S. Patent App. No. US 2010/0087470
1019	U.S. Patent No. 4,582,835
1020	Center for Drug Evaluation and Research, Approval Package for App. No. 22-410/S006/S007 (approval date 8/10/12) (“Film Approval Package”)
1021	Encyclopedia of Pharmaceutical Technology, 2 nd ed., Vol. I, Drug Delivery—Buccal Route (McElnay et al.) (“McElnay”)
1022	U.S. Patent No. 5,288,497 (“Stanley”)
1023	Declaration by Maureen Reitman, SC.D. (“Reitman Decl.”)
1024	Parkhurst A. Shore et al., <i>The Gastric Secretion of Drugs: A pH Partition Hypothesis</i> , 119 J. Pharmacology Exp. Ther. 361 (1957)
1025	Curriculum Vitae of Nandita Das, Ph.D.
1026	List of Materials Considered by Nandita Das, Ph.D.
1027	Telephone Conference Transcript, <i>Teva Pharmaceuticals USA, Inc. v. Monsol RX LLC and Indivior</i> , IPR2016-00280, IPR2016-00281, and IPR2016-00282 (Feb. 17, 2016)
1028	Declaration of Eleanor Yost in Support of Petitioner’s Motion to

	Correct Filing Date, IPR2016-00281, IPR2016-00282
1029	Declaration of Linda Rogers in Support of Petitioner's Motion to Correct Filing Date, IPR2016-00281, IPR2016-00282
1030	PRPS System Notification - Petition Submission IPR2016-00280
1031	PRPS System Notification - Petition Submission IPR2016-00281
1032	PRPS System Notification - Petition Submission IPR2016-00282
1033	500 7 th Ave, New York, NY FedEx Location Website Printout
1034	Telephone Conference Transcript, <i>Teva Pharmaceuticals USA, Inc. v. Indivior UK Ltd.</i> , IPR2016-00280 (May 16, 2016)

CERTIFICATE OF SERVICE

The undersigned hereby certifies that the foregoing: **PETITIONER'S
UPDATED EXHIBIT LIST** was served electronically via e-mail on May 25,
2016 on the following:

Andrea G. Reister

areister@cov.com

Enrique D. Longton

rlongton@cov.com

Dated: May 25, 2016

By: Molly R. Grammel/
Molly R. Grammel